

lipoprotein; Triglycerides; UK Biobank

Abstract

 Background: Causality between plasma triglyceride (TG) levels and atherosclerotic cardiovascular disease (ASCVD) risk remains controversial despite more than four decades of study and two recent landmark trials, STRENGTH and REDUCE-IT. Further unclear is the association between TG levels and non-atherosclerotic diseases across organ systems.

 Methods: Here, we conducted a phenome-wide, two-sample Mendelian randomization (MR) analysis using inverse-variance weighted (IVW) regression to systematically infer the causal effects of plasma TG levels on 2,600 disease traits in the European ancestry population of UK Biobank. For replication, we externally tested 221 nominally significant associations (*p* < 0.05) in an independent cohort from FinnGen. To account for potential horizontal pleiotropy and the influence of invalid instrumental variables, we performed sensitivity analyses using MR-Egger regression, weighted median estimator, and MR-PRESSO. Finally, we used multivariable MR controlling for correlated lipid fractions to distinguish the independent effect of plasma TG levels.

 Results: Our results identified 7 disease traits reaching Bonferroni-corrected significance in both 56 the discovery ($p < 1.92 \times 10^{-5}$) and replication analyses ($p < 2.26 \times 10^{-4}$), supporting a causal relationship between plasma TG levels and ASCVDs, including coronary artery disease (OR 58 1.33, 95% CI 1.24-1.43, $p = 2.47 \times 10^{-13}$). We also identified 12 disease traits that were Bonferroni-significant in the discovery or replication analysis and at least nominally significant 60 in the other analysis ($p < 0.05$), identifying plasma TG levels as a novel risk factor for 9 non-61 ASCVD diseases, including uterine leiomyoma (OR 1.19, 95% CI 1.10-1.29, $p = 1.17 \times 10^{-5}$).

Introduction

Methods

Study design and data sources

- We followed the guidelines published by Burgess et al. (Burgess et al., 2020) and the
- Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines
- (Skrivankova et al., 2021). Accordingly, we note that MR analyses rely on three important
- instrumental variable assumptions: (1) the genetic variant is directly associated with the
- exposure; (2) the genetic variant is unrelated to confounders between the exposure and outcome;
- 137 and (3) the genetic variant has no effect on the outcome other than through the exposure (Davey
- Smith & Ebrahim, 2003). This study uses three non-overlapping genome-wide association
- studies (GWAS). A schematic figure summarizes the study design (Fig 1).

Fig 1. Study overview.

 A schematic summarizing the study design. GLGC, Global Lipids Genetics Consortium; HDL, high-density lipoprotein; IVW, inverse-variance weighted; LDL, low-density lipoprotein; MR, Mendelian randomization; MR-PRESSO, Mendelian Randomization Pleiotropy RESidual Sum and Outlier; SNP, single-nucleotide polymorphism; TG, triglyceride; UKB, UK Biobank. Tier 1 (BB): At least Bonferroni-significant in both the discovery and replication analyses. Tier 2 (BN): At least Bonferroni-significant in the discovery analysis and at least nominally significant in the replication analysis. Tier 3 (NB): At least nominally significant in the discovery analysis and at least Bonferroni-significant in the replication analysis.

For primary and secondary analyses, we identified 3,086 single nucleotide

polymorphisms (SNP) associated with plasma TG levels in GLGC at a genome-wide

171 significance threshold of $p < 5 \times 10^{-8}$. A total of 141 independent SNPs were then selected at a

172 linkage disequilibrium (LD) threshold of r^2 < 0.05 using the 1000 Genomes LD European panel

as the reference population (Auton et al., 2015). To select independent SNPs, we used the

Disease outcomes

 As a phenome-wide investigation, this study examined many binary disease outcomes. For outcomes of primary and sensitivity analyses, we used genome-wide association summary statistics from the European ancestry subset of UKB. The focus on European ancestry was needed to reduce heterogeneity and maximize statistical power. Pan-UKB performed 16,000 188 genome-wide association studies in ~500,000 UKB participants of various ancestries using genetic and phenotypic data (PanUKBTeam, 2020). A total of 7,221 total phenotypes were categorized as "biomarker", "continuous", "categorical", "ICD-10 code", "phecode", or "prescription" (PanUKBTeam, 2020). We filtered for outcomes to retain categorical, ICD-10, and phecode types; non-null heritability in European ancestry as estimated by Pan-UKB; and relevance to disease, excluding medications. This yielded 2,600 traits for primary analysis. For outcomes of replication analysis, we used genome-wide association summary statistics from FinnGen. To allow for compatibility between UKB and FinnGen datasets, phenotypes coded as FinnGen "endpoint IDs" were mapped to ICD-10 codes or phecodes

Ethical approval

Results

Genetically proxied plasma TG levels and phenome-wide disease risk

262 In the discovery analysis, we identified nominally significant associations $(p < 0.05)$ between plasma TG levels and 598 disease traits in UKB (S1 Table). Of these, 39 disease traits were statistically significant after multiple testing correction with a conservative Bonferroni-265 corrected threshold ($p < 1.92 \times 10^{-5}$). As a positive control, plasma TG levels were positively 266 associated with gout with an odds ratio (OR) of 1.78 for gout (95% CI 1.52-2.09, $p = 7.41 \times 10^{-7}$ ¹¹), in agreement with prior studies (Yu et al., 2021). In the replication analysis, we identified nominally significant associations (*p* < 0.05) between plasma TG levels and 71 disease traits in FinnGen (S2 Table). Of these, 22 traits were Bonferroni-significant. A summary of the 19 most statistically significant and replicated results have been organized into three predefined tiers of evidence (Fig 2). We note that the magnitude of estimates from the discovery analysis were generally greater than those from replication analysis, especially among tier 1 and tier 2 associations, potentially as a manifestation of winner's curse bias (Göring et al., 2001).

Fig 2. Causal estimates of genetically proxied plasma TG levels on disease risk using IVW regression in UKB and FinnGen.

Causal estimates from inverse-variance weighted (IVW) regression are shown as odds ratios

-
- (OR) per 1 SD increase in plasma triglyceride (TG) levels (mmol/L). Asterisks indicate novel
- associations. Black indicates discovery analysis results using UKB. Red indicates replication
- analysis results using FinnGen. Horizontal lines represent 95% confidence intervals. Tier 1 (BB):

 At least Bonferroni-significant in both the discovery and replication analyses. Tier 2 (BN): At least Bonferroni-significant in the discovery analysis and at least nominally significant in the replication analysis. Tier 3 (NB): At least nominally significant in the discovery analysis and at least Bonferroni-significant in the replication analysis. Full results are provided in S1 and S2 Tables.

 For tier 1 results, genetically determined plasma TG levels were positively associated with 7 disease traits in both the discovery and replication analyses. These were Bonferroni- significant in both analyses, and all were related to dyslipidemias or ASCVD. Among traits related to ASCVD, the strongest association by statistical significance was for angina pectoris in 291 both the discovery UKB cohort (OR 1.39, 95% CI 1.29-1.51, $p = 2.11 \times 10^{-13}$) and the replication 292 FinnGen cohort (OR 1.30, 95% CI 1.24-1.37, $p = 1.25 \times 10^{-26}$). For tier 2 results, plasma TG levels were positively associated with 3 disease traits, including non-ASCVDs: gout, uterine leiomyoma, and "other aneurysms" (phecode-442). The strongest association by significance, after gout, was for leiomyoma of the uterus in both the discovery (OR 1.19, 95% CI 1.10-1.29, *p* $296 = 1.17 \times 10^{-5}$) and replication cohorts (OR 1.06, 95% CI 1.02-1.11, $p = 3.60 \times 10^{-3}$). For tier 3 results, 9 disease traits were identified, and a greater proportion were non-ASCVD traits. The strongest association by significance was for hypertension in both the discovery (OR 1.51, 95% CI 1.08-1.23, $p = 3.20 \times 10^{-5}$ and replication cohorts (OR 1.17, 95% CI 1.14-1.22, $p = 9.49 \times$ 10^{-20}).

-
-
-

Sensitivity analyses using MR-PRESSO, MR-Egger, and Weighted Median methods

 To account for potential horizontal pleiotropy bias due to outlier IVs, we next used the MR-PRESSO test on the 19 significant and replicated associations identified above, which were categorized into three tiers of statistical evidence. MR-PRESSO suspected outlier IVs for 16 of the 19 associations, and between 1 and 10 IVs were identified for 8 associations (S3 Table). We then re-ran IVW MR for these 8 associations after removing outlier IVs (S3 Table). Among tier 1 results, all 7 associations increased in significance after outlier removal (Fig 3). For tier 2 results, two of three associations had significant global MR-PRESSO test values but no outlier IVs were removed. For tier 3 results, seven of nine associations had significant global MR- PRESSO test values, and outlier IVs were removed for one of these associations (S3 Table), 314 which increased in significance: hypertension ($p = 3.20 \times 10^{-5}$ to $p = 2.80 \times 10^{-8}$). Importantly, all associations maintained the same effect direction after the MR-PRESSO outlier test, in keeping with the initial discovery analysis.

Fig 3. Causal estimates of genetically proxied plasma TG levels on disease risk using MR-

Egger, Weighted Median, and MR-PRESSO methods in UKB.

Shown are sensitivity analysis results from the discovery stage using instruments from GLGC

- 321 and outcomes from UKB. Levels of statistical significance are expressed as $-log_{10}(p)$ values.
- Associations with insignificant global MR-PRESSO test results (*p* > 0.05) were not rerun and do
- not have data points for IVW after MR-PRESSO. Tier 1 (BB): At least Bonferroni-significant in

Fig 4. Causal estimates of genetically proxied plasma TG levels on disease risk using

multivariable IVW regression controlling for plasma LDL-C and HDL-C levels in UKB.

- Shown are the multivariable MR results from the discovery analysis, using genetic instruments
- for plasma TG levels from GLGC and disease traits from UKB. Degrees of statistical
- significance are categorized into three tiers: Tier 1 (BB): At least Bonferroni-significant in both
- the discovery and replication analyses. Tier 2 (BN): At least Bonferroni-significant in the

- discovery analysis and at least nominally significant in the replication analysis. Tier 3 (NB): At
- least nominally significant in the discovery analysis and at least Bonferroni-significant in the
- replication analysis. Full results are provided in S4 Table.

Discussion

 We performed phenome-wide, two-sample MR to estimate the causal effects of plasma TG levels on a spectrum of human disease traits (*n* = 2,600) using a discovery cohort from UKB and a replication cohort from FinnGen. We report 7 disease traits reaching Bonferroni-corrected significance in both the discovery and replication analyses, which we categorized as tier 1 results. These traits were predominantly manifestations of ASCVD, such as ischemic heart disease, angina pectoris, and myocardial infarction. Using multivariable MR, we found that these associations remained even after controlling for LDL-C and HDL-C (Fig 4). We also identified 3 disease traits that are both Bonferroni-significant in the discovery analysis ($p < 1.92 \times 10^{-5}$) and 366 at least nominally significant in the replication analysis ($p < 0.05$), categorized as tier 2 results. Lastly, we identified 9 disease traits at least nominally significant in the discovery analysis and Bonferroni-significant in replication analysis, categorized as tier 3 results. Several of these disease traits have never been reported to be causally associated with TGs, introducing new opportunities for drug repurposing and further mechanistic studies. Our results are consistent with prior work suggesting that plasma TG levels are causally associated with ASCVD risk (Triglyceride Coronary Disease Genetics et al., 2010) (Castañer et al., 2020) (Do et al., 2013) (Dewey et al., 2016) (Holmes et al., 2015) (White et al., 2016) (Varbo et al., 2013) (Ibi et al., 2021) (Rosenson et al., 2021). We do not prove here that circulating TGs *per se* are directly atherogenic; rather, we show that plasma TG measurement, which comprises multiple classes of triglyceride-rich lipoproteins (TRL) and their remnants, captures a clinically significant mechanism that is causally associated with ASCVD (Rosenson et al., 2021). This interpretation is concordant with the emerging consensus that apolipoprotein B (apoB) particle number is a more important determinant of atherogenesis than LDL-C and that TRL particles are

 repurposing TG-lowering agents towards these diseases and pursuing mechanistic studies interrogating TG biology; however, RCTs are necessary to better evaluate clinical potential. Our results also identified a novel, negative causal association between plasma TG levels and alcoholic liver disease (ALD), suggesting that excessively reducing plasma TG levels may increase risk of this disease trait. A mechanistic explanation for this association remains elusive as previous studies on dysregulated lipid metabolism in liver disease have generally focused on non-alcoholic fatty liver disease (NAFLD). However, one animal study suggests that medium- chain TGs may decrease lipid peroxidation and reverse established alcoholic liver injury in rat models of ALD (Nanji et al., 1996). Nevertheless, that elevated TG levels may protect against ALD is surprising and requires validation. It remains unclear whether this association is only relevant to lifelong, chronic lowering of plasma TG levels rather than transient lowering by drug- based interventions. It is also unclear whether ALD could be prevented by increasing TG levels. Our finding emphasizes the potential intolerability of TG-lowering agents and the importance of maintaining these drugs' concentrations within therapeutic windows for patient safety. This study has several limitations. First, horizontal pleiotropy has been shown to be common in genetic variation, which can cause bias in MR testing (Verbanck et al., 2018) (Jordan et al., 2019). We used MR tests that are robust to horizontal pleiotropy including the MR- PRESSO test as well as MR-Egger and weighted median estimators as sensitivity analyses. Second, genetic variants confer exposures that are lifelong but small in effect size; thus, MR may over- or underestimate the effect sizes of pharmacological interventions. MR also cannot make comparisons between TG-lowering agents as it evaluates drug targets, not drug subclasses and unique pharmacodynamics (Gill et al., 2019) (Sofat et al., 2010). However, the utility of MR in drug target validation is well-established as estimates still indicate the presence and direction of

 causality (Gill et al., 2021). Third, we were unable to reliably map "categorical" traits from UKB to corresponding traits in FinnGen for all traits, testing for replication only 221 of the 598 associations that were nominally significant in the primary analysis. Moreover, ICD-10 codes and phecodes are imperfect descriptors of disease, liable to misclassification. Lastly, we acknowledge that this study was restricted to populations of European ancestry, limiting the generalizability of our findings. A recent study observed comparable MR estimates for the causal effects of lipid traits on ischemic stroke risk between African and European ancestry individuals (Fatumo et al., 2021), suggesting the potential generalizability of MR results across ancestries in some specific cases. Nevertheless, trans-ancestry MR analyses are warranted to validate our study's findings in diverse ancestry populations. In conclusion, this study demonstrates a high-throughput application of two-sample MR to estimate the causal effects of plasma TGs on disease risk phenome-wide. With the proliferation of multiomic data, this systematic approach could be generalized to study the causal effects of serum biomarkers at scale to support the prioritization of targets for drug discovery. Further studies are needed however to consider the functional and qualitative attributes of TRL and TG subtypes. Metabolomic data partitioning TRLs by size and composition may enable this to identify the subcomponent of a plasma TG measurement that drives disease risk (Holmes et al., 2015). Diverse study designs are warranted to further triangulate evidence for the causal effects of plasma TG levels on disease risk.

Acknowledgements

We acknowledge the participants and investigators of the FinnGen and UKB studies.

Competing interests

- RD reports receiving grants from AstraZeneca; grants and non-financial support from Goldfinch
- Bio; being a scientific co-founder, consultant, and equity holder (pending) for Pensieve Health;
- and a consultant for Variant Bio, all unrelated to this work. RSR reports receiving grants from
- Amgen, Arrowhead, Lilly, Novartis and Regeneron; consulting fees from Amgen, Arrowhead,
- Lilly, Novartis and Regeneron; honoraria for non-promotional lectures from Amgen, Kowa and
- Regeneron, royalties from Wolters Kluwer (UpToDate); and stock holdings in MediMergent,
- LLC.

References

- Albrink, M. J., & Man, E. B. (1959). Serum Triglycerides in Coronary Artery Disease. *A.M.A.*
- *Archives of Internal Medicine*, *103*(1), 4-8.
- https://doi.org/10.1001/archinte.1959.00270010010002
- Allara, E., Morani, G., Carter, P., Gkatzionis, A., Zuber, V., Foley, C. N., Rees, J. M. B., Mason,
- A. M., Bell, S., Gill, D., Lindström, S., Butterworth, A. S., Angelantonio, E. D., Peters,
- J., & Burgess, S. (2019). Genetic Determinants of Lipids and Cardiovascular Disease
- Outcomes. *Circulation: Genomic and Precision Medicine*, *12*(12), e002711.
- https://doi.org/doi:10.1161/CIRCGEN.119.002711
- Arrowhead. (2021a). *Study of ARO-ANG3 in Adults With Mixed Dyslipidemia (ARCHES-2)*. U.S.
- National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT04832971
- Arrowhead. (2021b). *Study of ARO-APOC3 in Adults With Mixed Dyslipidemia (MUIR)*. U.S.
- National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT04998201
- Auton, A., Abecasis, G. R., Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R.,
- Chakravarti, A., Clark, A. G., Donnelly, P., Eichler, E. E., Flicek, P., Gabriel, S. B.,
- Gibbs, R. A., Green, E. D., Hurles, M. E., Knoppers, B. M., Korbel, J. O., Lander, E. S.,
- Lee, C., . . . Abecasis, G. R. (2015). A global reference for human genetic variation.
- *Nature*, *526*(7571), 68-74. https://doi.org/10.1038/nature15393
- Baigent, C., Keech, A., Kearney, P. M., Blackwell, L., Buck, G., Pollicino, C., Kirby, A.,
- Sourjina, T., Peto, R., Collins, R., & Simes, R. (2005). Efficacy and safety of cholesterol-
- lowering treatment: prospective meta-analysis of data from 90,056 participants in 14
- randomised trials of statins. *Lancet (London, England)*, *366*(9493), 1267-1278.
- https://doi.org/10.1016/s0140-6736(05)67394-1

- T., Juliano, R. A., Jiao, L., Granowitz, C., Tardif, J.-C., & Ballantyne, C. M. (2019).
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. *New*
- *England Journal of Medicine*, *380*(1), 11-22. https://doi.org/10.1056/nejmoa1812792
- Böhm, S. K. (2021). Excessive Body Weight and Diverticular Disease. *Visc Med*, *37*(5), 372-
- 382. https://doi.org/10.1159/000518674
- Bowden, J., Davey Smith, G., & Burgess, S. (2015). Mendelian randomization with invalid

instruments: effect estimation and bias detection through Egger regression. *International*

Journal of Epidemiology, *44*(2), 512-525. https://doi.org/10.1093/ije/dyv080

Bowden, J., Davey Smith, G., Haycock, P. C., & Burgess, S. (2016). Consistent Estimation in

 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genetic Epidemiology*, *40*(4), 304-314. https://doi.org/10.1002/gepi.21965

- Burgess, S., Butterworth, A., & Thompson, S. G. (2013). Mendelian Randomization Analysis
- With Multiple Genetic Variants Using Summarized Data. *Genetic Epidemiology*, *37*(7),
- 658-665. https://doi.org/10.1002/gepi.21758
- Burgess, S., Davey Smith, G., Davies, N. M., Dudbridge, F., Gill, D., Glymour, M. M., Hartwig,
- F. P., Holmes, M. V., Minelli, C., Relton, C. L., & Theodoratou, E. (2020). Guidelines
- for performing Mendelian randomization investigations. *Wellcome open research*, *4*, 186.
- https://doi.org/10.12688/wellcomeopenres.15555.2
- Burgess, S., Davies, N. M., & Thompson, S. G. (2016). Bias due to participant overlap in two-
- sample Mendelian randomization. *Genet Epidemiol*, *40*(7), 597-608.
- https://doi.org/10.1002/gepi.21998

- Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L. T., Sharp, K., Motyer, A., Vukcevic,
- D., Delaneau, O., O'Connell, J., Cortes, A., Welsh, S., Young, A., Effingham, M.,
- McVean, G., Leslie, S., Allen, N., Donnelly, P., & Marchini, J. (2018). The UK Biobank
- resource with deep phenotyping and genomic data. *Nature*, *562*(7726), 203-209.
- https://doi.org/10.1038/s41586-018-0579-z
- Castañer, O., Pintó, X., Subirana, I., Amor, A. J., Ros, E., Hernáez, Á., Martínez-González, M.,
- Corella, D., Salas-Salvadó, J., Estruch, R., Lapetra, J., Gómez-Gracia, E., Alonso-Gomez,
- A. M., Fiol, M., Serra-Majem, L., Corbella, E., Benaiges, D., Sorli, J. V., Ruiz-Canela,
- M., . . . Fitó, M. (2020). Remnant Cholesterol, Not LDL Cholesterol, Is Associated With
- Incident Cardiovascular Disease. *J Am Coll Cardiol*, *76*(23), 2712-2724.
- https://doi.org/10.1016/j.jacc.2020.10.008
- Cromwell, W. C., Otvos, J. D., Keyes, M. J., Pencina, M. J., Sullivan, L., Vasan, R. S., Wilson,
- P. W., & D'Agostino, R. B. (2007). LDL Particle Number and Risk of Future
- Cardiovascular Disease in the Framingham Offspring Study Implications for LDL
- Management. *J Clin Lipidol*, *1*(6), 583-592. https://doi.org/10.1016/j.jacl.2007.10.001
- Crosby, J., Peloso, G. M., Auer, P. L., Crosslin, D. R., Stitziel, N. O., Lange, L. A., Lu, Y., Tang,
- Z. Z., Zhang, H., Hindy, G., Masca, N., Stirrups, K., Kanoni, S., Do, R., Jun, G., Hu, Y.,
- Kang, H. M., Xue, C., Goel, A., . . . Kathiresan, S. (2014). Loss-of-function mutations in
- APOC3, triglycerides, and coronary disease. *N Engl J Med*, *371*(1), 22-31.
- https://doi.org/10.1056/NEJMoa1307095
- Davey Smith, G., & Ebrahim, S. (2003). 'Mendelian randomization': can genetic epidemiology
- contribute to understanding environmental determinants of disease?*. *International*
- *Journal of Epidemiology*, *32*(1), 1-22. https://doi.org/10.1093/ije/dyg070

- inference in epidemiological studies. *Human molecular genetics*, *23*(R1), R89-R98.
- https://doi.org/10.1093/hmg/ddu328
- Deloukas, P., Kanoni, S., Willenborg, C., Farrall, M., Assimes, T. L., Thompson, J. R.,
- Ingelsson, E., Saleheen, D., Erdmann, J., Goldstein, B. A., Stirrups, K., König, I. R.,
- Cazier, J. B., Johansson, A., Hall, A. S., Lee, J. Y., Willer, C. J., Chambers, J. C., Esko,
- T., . . . Samani, N. J. (2013). Large-scale association analysis identifies new risk loci for
- coronary artery disease. *Nat Genet*, *45*(1), 25-33. https://doi.org/10.1038/ng.2480
- Dewey, F. E., Gusarova, V., Dunbar, R. L., O'Dushlaine, C., Schurmann, C., Gottesman, O.,
- McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., Leader, J. B., Murray, M. F.,
- Ritchie, M. D., Kirchner, H. L., Habegger, L., Lopez, A., Penn, J., Zhao, A., Shao, W., . .
- . Baras, A. (2017). Genetic and Pharmacologic Inactivation of ANGPTL3 and
- Cardiovascular Disease. *N Engl J Med*, *377*(3), 211-221.
- https://doi.org/10.1056/NEJMoa1612790
- Dewey, F. E., Gusarova, V., O'Dushlaine, C., Gottesman, O., Trejos, J., Hunt, C., Van Hout, C.
- V., Habegger, L., Buckler, D., Lai, K.-M. V., Leader, J. B., Murray, M. F., Ritchie, M.
- D., Kirchner, H. L., Ledbetter, D. H., Penn, J., Lopez, A., Borecki, I. B., Overton, J. D., .
- . . Shuldiner, A. R. (2016). Inactivating Variants in ANGPTL4 and Risk of Coronary
- Artery Disease. *New England Journal of Medicine*, *374*(12), 1123-1133.
- https://doi.org/10.1056/nejmoa1510926
- Do, R., Willer, C. J., Schmidt, E. M., Sengupta, S., Gao, C., Peloso, G. M., Gustafsson, S.,
- Kanoni, S., Ganna, A., Chen, J., Buchkovich, M. L., Mora, S., Beckmann, J. S., Bragg-
- Gresham, J. L., Chang, H. Y., Demirkan, A., Den Hertog, H. M., Donnelly, L. A., Ehret,

- https://doi.org/10.1038/ng.2795
- Doi, T., Langsted, A., & Nordestgaard, B. G. (2021). A possible explanation for the contrasting
- results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs. *European*
- *Heart Journal*, *42*(47), 4807-4817. https://doi.org/10.1093/eurheartj/ehab555
- Eckel, R. H., Grundy, S. M., & Zimmet, P. Z. (2005). The metabolic syndrome. *The Lancet*,

365(9468), 1415-1428. https://doi.org/https://doi.org/10.1016/S0140-6736(05)66378-7

- Fatumo, S., Karhunen, V., Chikowore, T., Sounkou, T., Udosen, B., Ezenwa, C., Nakabuye, M.,
- Soremekun, O., Daghlas, I., Ryan, D. K., Taylor, A., Mason, A. M., Damrauer, S. M.,
- Vujkovic, M., Keene, K. L., Fornage, M., Järvelin, M.-R., Burgess, S., & Gill, D. (2021).
- Metabolic Traits and Stroke Risk in Individuals of African Ancestry: Mendelian
- Randomization Analysis. *Stroke*, *52*(8), 2680-2684.
- https://doi.org/doi:10.1161/STROKEAHA.121.034747
- Ference, B. A., Kastelein, J. J. P., Ray, K. K., Ginsberg, H. N., Chapman, M. J., Packard, C. J.,
- Laufs, U., Oliver-Williams, C., Wood, A. M., Butterworth, A. S., Di Angelantonio, E.,
- Danesh, J., Nicholls, S. J., Bhatt, D. L., Sabatine, M. S., & Catapano, A. L. (2019).
- Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR
- Variants With Risk of Coronary Heart Disease. *JAMA*, *321*(4), 364-373.
- https://doi.org/10.1001/jama.2018.20045
- FinnGen. (2020). *FinnGen Documentation of R4 Release*
- https://finngen.gitbook.io/documentation/

- body composition in diverticular disease. *Int J Colorectal Dis*, *33*(9), 1299-1302.
- https://doi.org/10.1007/s00384-018-3058-y
- Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K.,
- Kaitaniemi, P., Koskinen, P., Manninen, V., Mäenpää, H., Mälkönen, M., Mänttäri, M.,
- Norola, S., Pasternack, A., Pikkarainen, J., Romo, M., Sjöblom, T., & Nikkilä, E. A.
- (1987). Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-
- Aged Men with Dyslipidemia. *New England Journal of Medicine*, *317*(20), 1237-1245.
- https://doi.org/10.1056/NEJM198711123172001
- Fry, A., Littlejohns, T. J., Sudlow, C., Doherty, N., Adamska, L., Sprosen, T., Collins, R., &
- Allen, N. E. (2017). Comparison of Sociodemographic and Health-Related
- Characteristics of UK Biobank Participants With Those of the General Population.
- *American Journal of Epidemiology*, *186*(9), 1026-1034.
- https://doi.org/10.1093/aje/kwx246
- Gaba, P., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B.,
- Juliano, R. A., Jiao, L., Doyle, R. T., Granowitz, C., Tardif, J.-C., Giugliano, R. P.,
- Martens, F. M. A. C., Gibson, C. M., & Ballantyne, C. M. (2022). Prevention of
- Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With
- Prior Myocardial Infarction. *Journal of the American College of Cardiology*, *79*(17),
- 1660-1671. https://doi.org/https://doi.org/10.1016/j.jacc.2022.02.035
- Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R.
- S., Hughes, S. G., Viney, N. J., Graham, M. J., Crooke, R. M., Witztum, J. L., Brunzell,
- J. D., & Kastelein, J. J. (2015). Antisense Inhibition of Apolipoprotein C-III in Patients

with Hypertriglyceridemia. *N Engl J Med*, *373*(5), 438-447.

- https://doi.org/10.1056/NEJMoa1400283
- Gaudet, D., Gipe, D. A., Pordy, R., Ahmad, Z., Cuchel, M., Shah, P. K., Chyu, K. Y., Sasiela, W.
- J., Chan, K. C., Brisson, D., Khoury, E., Banerjee, P., Gusarova, V., Gromada, J., Stahl,
- N., Yancopoulos, G. D., & Hovingh, G. K. (2017). ANGPTL3 Inhibition in Homozygous
- Familial Hypercholesterolemia. *N Engl J Med*, *377*(3), 296-297.
- https://doi.org/10.1056/NEJMc1705994
- Gill, D., Georgakis, M. K., Koskeridis, F., Jiang, L., Feng, Q., Wei, W.-Q., Theodoratou, E.,
- Elliott, P., Denny, J. C., Malik, R., Evangelou, E., Dehghan, A., Dichgans, M., &
- Tzoulaki, I. (2019). Use of Genetic Variants Related to Antihypertensive Drugs to Inform

on Efficacy and Side Effects. *Circulation*, *140*(4), 270-279.

- https://doi.org/10.1161/circulationaha.118.038814
- Gill, D., Georgakis, M. K., Walker, V. M., Schmidt, A. F., Gkatzionis, A., Freitag, D. F., Finan,
- C., Hingorani, A. D., Howson, J. M. M., Burgess, S., Swerdlow, D. I., Davey Smith, G.,
- Holmes, M. V., Dichgans, M., Scott, R. A., Zheng, J., Psaty, B. M., & Davies, N. M.
- (2021). Mendelian randomization for studying the effects of perturbing drug targets.
- *Wellcome open research*, *6*, 16-16. https://doi.org/10.12688/wellcomeopenres.16544.2
- Goldberg, I. J., Eckel, R. H., & McPherson, R. (2011). Triglycerides and heart disease: still a
- hypothesis? *Arteriosclerosis, thrombosis, and vascular biology*, *31*(8), 1716-1725.
- https://doi.org/10.1161/ATVBAHA.111.226100
- Göring, H. H., Terwilliger, J. D., & Blangero, J. (2001). Large upward bias in estimation of
- locus-specific effects from genomewide scans. *American journal of human genetics*,
- *69*(6), 1357-1369. https://doi.org/10.1086/324471

- Graham, M. J., Lee, R. G., Brandt, T. A., Tai, L.-J., Fu, W., Peralta, R., Yu, R., Hurh, E., Paz, E.,
- McEvoy, B. W., Baker, B. F., Pham, N. C., Digenio, A., Hughes, S. G., Geary, R. S.,
- Witztum, J. L., Crooke, R. M., & Tsimikas, S. (2017). Cardiovascular and Metabolic
- Effects of ANGPTL3 Antisense Oligonucleotides. *New England Journal of Medicine*,
- *377*(3), 222-232. https://doi.org/10.1056/NEJMoa1701329
- Group, T. A. S. (2010). Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. *New England Journal of Medicine*, *362*(17), 1563-1574.
- https://doi.org/10.1056/NEJMoa1001282
- Harrison, S. C., Holmes, M. V., Burgess, S., Asselbergs, F. W., Jones, G. T., Baas, A. F., van 't
- Hof, F. N., de Bakker, P. I. W., Blankensteijn, J. D., Powell, J. T., Saratzis, A., de Borst,
- G. J., Swerdlow, D. I., van der Graaf, Y., van Rij, A. M., Carey, D. J., Elmore, J. R.,
- Tromp, G., Kuivaniemi, H., . . . Humphries, S. E. (2018). Genetic Association of Lipids
- and Lipid Drug Targets With Abdominal Aortic Aneurysm: A Meta-analysis. *JAMA*

cardiology, *3*(1), 26-33. https://doi.org/10.1001/jamacardio.2017.4293

- Holmes, M. V., Asselbergs, F. W., Palmer, T. M., Drenos, F., Lanktree, M. B., Nelson, C. P.,
- Dale, C. E., Padmanabhan, S., Finan, C., Swerdlow, D. I., Tragante, V., van Iperen, E. P.,
- Sivapalaratnam, S., Shah, S., Elbers, C. C., Shah, T., Engmann, J., Giambartolomei, C.,
- White, J., . . . Casas, J. P. (2015). Mendelian randomization of blood lipids for coronary
- heart disease. *Eur Heart J*, *36*(9), 539-550. https://doi.org/10.1093/eurheartj/eht571
- Ibi, D., Blauw, L. L., Noordam, R., Dollé, M. E. T., Jukema, J. W., Rosendaal, F. R.,
- Christodoulides, C., Neville, M. J., Koivula, R., Rensen, P. C. N., Karpe, F., & van Dijk,
- K. W. (2021). Triglyceride-lowering LPL alleles combined with LDL-C-lowering alleles

- are associated with an additively improved lipoprotein profile. *Atherosclerosis*, *328*, 144-
- 152. https://doi.org/10.1016/j.atherosclerosis.2021.04.015
- Jordan, D. M., Verbanck, M., & Do, R. (2019). HOPS: a quantitative score reveals pervasive
- horizontal pleiotropy in human genetic variation is driven by extreme polygenicity of
- human traits and diseases. *Genome Biol*, *20*(1), 222. https://doi.org/10.1186/s13059-019-
- 1844-7
- Keech, A., Simes, R. J., Barter, P., Best, J., Scott, R., Taskinen, M. R., Forder, P., Pillai, A.,
- Davis, T., Glasziou, P., Drury, P., Kesäniemi, Y. A., Sullivan, D., Hunt, D., Colman, P.,
- d'Emden, M., Whiting, M., Ehnholm, C., & Laakso, M. (2005). Effects of long-term
- fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus
- (the FIELD study): randomised controlled trial. *Lancet (London, England)*, *366*(9500),

1849-1861. https://doi.org/10.1016/s0140-6736(05)67667-2

- Kurki, M. I., Karjalainen, J., Palta, P., Sipilä, T. P., Kristiansson, K., Donner, K., Reeve, M. P.,
- Laivuori, H., Aavikko, M., Kaunisto, M. A., Loukola, A., Lahtela, E., Mattsson, H.,
- Laiho, P., Della Briotta Parolo, P., Lehisto, A., Kanai, M., Mars, N., Rämö, J., . . .
- Palotie, A. (2022). FinnGen: Unique genetic insights from combining isolated population and national health register data. *medRxiv*, 2022.2003.2003.22271360.
- https://doi.org/10.1101/2022.03.03.22271360
- Lee, H. C., Chen, C. C., Tsai, W. C., Lin, H. T., Shiao, Y. L., Sheu, S. H., Wu, B. N., Chen, C.
- H., & Lai, W. T. (2017). Very-Low-Density Lipoprotein of Metabolic Syndrome
- Modulates Gap Junctions and Slows Cardiac Conduction. *Sci Rep*, *7*(1), 12050.
- https://doi.org/10.1038/s41598-017-11416-5

- Ference, B., Stein, E., Stroes, E. S., Braunwald, E., Ellinor, P. T., Lubitz, S. A., Ruff, C.
- T., & Sabatine, M. S. (2021). Association of Apolipoprotein B–Containing Lipoproteins
- and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis:
- Distinguishing Between Particle Concentration, Type, and Content. *JAMA cardiology*.
- https://doi.org/10.1001/jamacardio.2021.5083
- Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A.
- C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., Lennie, T. A., Levi, M.,
- Mazzone, T., & Pennathur, S. (2011). Triglycerides and Cardiovascular Disease.
- *Circulation*, *123*(20), 2292-2333. https://doi.org/doi:10.1161/CIR.0b013e3182160726
- Musunuru, K., Pirruccello, J. P., Do, R., Peloso, G. M., Guiducci, C., Sougnez, C., Garimella, K.
- V., Fisher, S., Abreu, J., Barry, A. J., Fennell, T., Banks, E., Ambrogio, L., Cibulskis, K.,
- Kernytsky, A., Gonzalez, E., Rudzicz, N., Engert, J. C., DePristo, M. A., . . . Kathiresan,
- S. (2010). Exome sequencing, ANGPTL3 mutations, and familial combined
- hypolipidemia. *N Engl J Med*, *363*(23), 2220-2227.
- https://doi.org/10.1056/NEJMoa1002926
- Nanji, A. A., Yang, E. K., Fogt, F., Sadrzadeh, S. M., & Dannenberg, A. J. (1996). Medium

chain triglycerides and vitamin E reduce the severity of established experimental

- alcoholic liver disease. *Journal of Pharmacology and Experimental Therapeutics*, *277*(3),
- 1694-1700. https://jpet.aspetjournals.org/content/jpet/277/3/1694.full.pdf
- Nicholls, S. J., Lincoff, A. M., Garcia, M., Bash, D., Ballantyne, C. M., Barter, P. J., Davidson,
- M. H., Kastelein, J. J. P., Koenig, W., McGuire, D. K., Mozaffarian, D., Ridker, P. M.,
- Ray, K. K., Katona, B. G., Himmelmann, A., Loss, L. E., Rensfeldt, M., Lundström, T.,

- Qin, Z., Zhao, J., Geng, J., Chang, K., Liao, R., & Su, B. (2021). Higher Triglyceride–Glucose
- Index Is Associated With Increased Likelihood of Kidney Stones [Original Research].
- *Frontiers in Endocrinology*, *12*. https://doi.org/10.3389/fendo.2021.774567
- R Core Team. (2021). *R: A language and environment for statistical computing*. In R Foundation
- for Statistical Computing. https://www.R-project.org/
- Richardson, T. G., Sanderson, E., Palmer, T. M., Ala-Korpela, M., Ference, B. A., Davey Smith,
- G., & Holmes, M. V. (2020). Evaluating the relationship between circulating lipoprotein
- lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian
- randomisation analysis. *PLOS Medicine*, *17*(3), e1003062-e1003062.
- https://doi.org/10.1371/journal.pmed.1003062
- Rosenson, R. S., & Goonewardena, S. N. (2021). The Residual Risk Odyssey: From LDL to
- Lp(a)∗. *Journal of the American College of Cardiology*, *78*(5), 434-436.
- https://doi.org/https://doi.org/10.1016/j.jacc.2021.04.103
- Rosenson, R. S., Shaik, A., & Song, W. (2021). New Therapies for Lowering Triglyceride-Rich
- Lipoproteins: JACC Focus Seminar 3/4. *Journal of the American College of Cardiology*,
- *78*(18), 1817-1830. https://doi.org/https://doi.org/10.1016/j.jacc.2021.08.051
- Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Ammirati, E., Baddour, L. M.,
- Barengo, N. C., Beaton, A. Z., Benjamin, E. J., Benziger, C. P., Bonny, A., Brauer, M.,
- Brodmann, M., Cahill, T. J., Carapetis, J., Catapano, A. L., Chugh, S. S., Cooper, L. T.,
- Coresh, J., . . . Fuster, V. (2020). Global Burden of Cardiovascular Diseases and Risk
- Factors, 1990–2019: Update From the GBD 2019 Study. *Journal of the American*
- *College of Cardiology*, *76*(25), 2982-3021.
- https://doi.org/https://doi.org/10.1016/j.jacc.2020.11.010

- Sanderson, E. (2021). Multivariable Mendelian Randomization and Mediation. *Cold Spring*
- *Harbor Perspectives in Medicine*, *11*(2), a038984.
- https://doi.org/10.1101/cshperspect.a038984
- Shaik, A., & Rosenson, R. S. (2021). Genetics of Triglyceride-Rich Lipoproteins Guide
- Identification of Pharmacotherapy for Cardiovascular Risk Reduction. *Cardiovascular*

Drugs and Therapy, *35*(3), 677-690. https://doi.org/10.1007/s10557-021-07168-0

- Shih, C. W., Chen, Y. H., & Chen, W. L. (2022). Percentage of body fat is associated with
- increased risk of diverticulosis: A cross sectional study. *PLOS ONE*, *17*(3), e0264746.
- https://doi.org/10.1371/journal.pone.0264746
- Skrivankova, V. W., Richmond, R. C., Woolf, B. A. R., Yarmolinsky, J., Davies, N. M.,
- Swanson, S. A., VanderWeele, T. J., Higgins, J. P. T., Timpson, N. J., Dimou, N.,
- Langenberg, C., Golub, R. M., Loder, E. W., Gallo, V., Tybjaerg-Hansen, A., Davey
- Smith, G., Egger, M., & Richards, J. B. (2021). Strengthening the Reporting of
- Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-
- MR Statement. *JAMA*, *326*(16), 1614-1621. https://doi.org/10.1001/jama.2021.18236
- Smith, J. G., Luk, K., Schulz, C.-A., Engert, J. C., Do, R., Hindy, G., Rukh, G., Dufresne, L.,
- Almgren, P., Owens, D. S., Harris, T. B., Peloso, G. M., Kerr, K. F., Wong, Q., Smith, A.
- V., Budoff, M. J., Rotter, J. I., Cupples, L. A., Rich, S., . . . Aging Research in Genetic
- Epidemiology Extracoronary Calcium Working, G. (2014). Association of Low-Density
- Lipoprotein Cholesterol–Related Genetic Variants With Aortic Valve Calcium and
- Incident Aortic Stenosis. *JAMA*, *312*(17), 1764-1771.
- https://doi.org/10.1001/jama.2014.13959

- (2016). Uterine fibroids and cardiovascular risk. *Human Reproduction*, *31*(12), 2689-
- 2703. https://doi.org/10.1093/humrep/dew249
- Varbo, A., Benn, M., Tybjærg-Hansen, A., Jørgensen, A. B., Frikke-Schmidt, R., &
- Nordestgaard, B. G. (2013). Remnant cholesterol as a causal risk factor for ischemic
- heart disease. *J Am Coll Cardiol*, *61*(4), 427-436.
- https://doi.org/10.1016/j.jacc.2012.08.1026
- Verbanck, M., Chen, C.-Y., Neale, B., & Do, R. (2018). Detection of widespread horizontal
- pleiotropy in causal relationships inferred from Mendelian randomization between
- complex traits and diseases. *Nature Genetics*, *50*(5), 693-698.
- https://doi.org/10.1038/s41588-018-0099-7
- White, J., Swerdlow, D. I., Preiss, D., Fairhurst-Hunter, Z., Keating, B. J., Asselbergs, F. W.,
- Sattar, N., Humphries, S. E., Hingorani, A. D., & Holmes, M. V. (2016). Association of
- Lipid Fractions With Risks for Coronary Artery Disease and Diabetes. *JAMA cardiology*,

1(6), 692-699. https://doi.org/10.1001/jamacardio.2016.1884

- Willer, C. J., Schmidt, E. M., Sengupta, S., Peloso, G. M., Gustafsson, S., Kanoni, S., Ganna, A.,
- Chen, J., Buchkovich, M. L., Mora, S., Beckmann, J. S., Bragg-Gresham, J. L., Chang, H.
- Y., Demirkan, A., Den Hertog, H. M., Do, R., Donnelly, L. A., Ehret, G. B., Esko, T., . . .
- Abecasis, G. R. (2013). Discovery and refinement of loci associated with lipid levels. *Nat*
- *Genet*, *45*(11), 1274-1283. https://doi.org/10.1038/ng.2797
- Yu, X., Wang, T., Huang, S., & Zeng, P. (2021). Evaluation of the causal effects of blood lipid
- levels on gout with summary level GWAS data: two-sample Mendelian randomization
- and mediation analysis. *Journal of Human Genetics*, *66*(5), 465-473.
- https://doi.org/10.1038/s10038-020-00863-0

- Zewinger, S., Reiser, J., Jankowski, V., Alansary, D., Hahm, E., Triem, S., Klug, M., Schunk, S.
- J., Schmit, D., Kramann, R., Körbel, C., Ampofo, E., Laschke, M. W., Selejan, S.-R.,
- Paschen, A., Herter, T., Schuster, S., Silbernagel, G., Sester, M., . . . Speer, T. (2020).
- Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome
- activation. *Nature Immunology*, *21*(1), 30-41. https://doi.org/10.1038/s41590-019-0548-1

Supplementary files

S1 Table. Causal estimates of plasma TG levels on 2,600 traits in UKB using multiple MR methods.

- Shown are the estimates, standard deviations, and *p*-values of MR results using IVW, MR-Egger,
- and Weighted Median methods. 141 SNPs were used as instrumental variables to proxy plasma
- 807 TG levels. A Bonferroni threshold for statistical significance was set to $p < 0.05 / 2600 = 1.92 \times$
- 10^{-5} for this discovery analysis.
-

```
810 S2 Table. Causal estimates of plasma TG levels on 221 traits in FinnGen using multiple
```
- **MR methods.**
- Shown are the estimates, standard deviations, and *p*-values of MR results using IVW, MR-Egger,
- and Weighted Median methods. 1,248 SNPs were used as instrumental variables to proxy plasma
- 814 TG levels. A Bonferroni threshold for statistical significance was set to $p < 0.05 / 221 = 2.26 \times$
- 10^{-4} for this replication analysis.

S3 Table. IVW-MR estimates of significant and replicated associations (Tier 1-3) after MR-PRESSO outlier tests using UKB data.

 Shown are the estimates, standard deviations, and *p*-values of IVW-MR results in the discovery analysis, before and after outlier IV removal, for significant and replicated traits (tier 1-3) that 821 had significant MR-PRESSO global test results $(p < 0.05)$ in the primary IVW analysis of the discovery UKB cohort.

S4 Table. Multivariable IVW-MR estimates of plasma TG levels on significant and

replicated associations (Tier 1-3) using UKB data.

- Shown are the estimates, standard deviations, and *p*-values of multivariable IVW-MR results
- 827 controlling for HDL-C, LDL-C, or both, in the discovery stage. Only tier 1-3 results significant
- and replicated as predefined in the methods were examined in this analysis.